

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

14 October 2025



CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")

Positive Preclinical Data in Prostate Cancer and Prestigious Collaborative Doctoral Award

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, today is pleased to announce significant preclinical findings and a new research collaboration that mark key milestones in the development of its innovative ChemoSeed® platform in prostate cancer.

Prostate cancer, the most prevalent cancer in men, is the second programme in CRISM's pipeline of product opportunities using the implantable ChemoSeed drug delivery platform. The Company's most advanced programme, irinotecan-ChemoSeed in glioblastoma, remains on track for the first patients to be dosed in an open label Phase 2 clinical trial in early 2026.

In vitro studies conducted by CRISM Therapeutics have demonstrated that the sustained administration of docetaxel to prostate cancer cell lines is significantly more effective than the intermittent dosing schedules currently used in the standard of care.

Sustained administration killed 72% of the prostate cancer cells compared with 65% with intermittent dosing. Furthermore, the concentration of docetaxel needed to inhibit 50% (IC₅₀) of prostate cancer cells from growing was 3.5nM for sustained administration compared with 9.8nM for intermittent dosing. The lower the IC₅₀, the more potent the treatment. Finally, at lower doses sustained administration of docetaxel resulted in continued reduction of prostate cancer cells for 12 days, whereas with intermittent dosing there was less reduction in the prostate cancer cells and the cells started to regrow by day 9.

These findings strongly support the hypothesis that sustained, localised delivery of chemotherapy, enabled by CRISM's proprietary ChemoSeed drug delivery platform, could substantially enhance the efficacy of docetaxel, a generic chemotherapy drug, in the treatment of prostate cancer. Furthermore, with ChemoSeed this increase in efficacy could be achieved with lower amounts of docetaxel being given to the patient reducing the unwanted side effects typically seen with this drug.

In addition, CRISM has successfully formulated docetaxel within the ChemoSeed platform, achieving sustained drug release over a period of at least 28 days. This major technical milestone confirms the feasibility of using ChemoSeed for prolonged, controlled delivery of docetaxel directly into prostate tumours, addressing a major limitation of current systemic chemotherapy approaches.

Further strengthening its R&D capabilities, CRISM Therapeutics is proud to announce it has been awarded a prestigious Department for the Economy ("DfE") Collaborative Doctoral Partnership ("CDP") studentship in collaboration with Ulster University. This partnership will support the ongoing development of docetaxel-ChemoSeed and explore its application in the personalised treatment of prostate cancer, including potential patient-specific dosing strategies and tumour-targeting delivery models. The DfE will cover the university tuition fees and provide a maintenance stipend to support the doctoral candidate's

living expenses.

Andrew Webb, Chief Executive Officer of CRISM Therapeutics, commented:

"These developments represent a major step forward in our mission to improve outcomes for prostate cancer patients by leveraging our ChemoSeed drug delivery platform. The data clearly suggest that delivering chemotherapy locally and continuously, rather than intermittently and systemically, could provide a much-needed improvement in therapeutic efficacy. Our partnership with Ulster University will further accelerate our progress and help bring this innovative treatment to patients faster. We welcome discussions with potential partners and collaborators as we build momentum towards first-in-human clinical trials."

-Ends-

Enquiries:

**Company
CRISM Therapeutics
Corporation**

Andrew Webb, CEO
Chris McConville, CSO
via Burson Buchanan

**Nomad and Broker
S.P. Angel Corporate
Finance LLP**

Richard Morrison
Vadim Alexandre
Adam Cowl
+44 (0) 20 3470 0470

**Financial PR
Burson Buchanan**

Mark Court / Jamie Hooper
CRISM@buchanancomms.co.uk
+44 (0) 20 7466 5000

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in patients with surgically resectable glioblastoma in Q1 2026.

For more information please visit: <https://www.crismtherapeutics.com/>

The Company's LEI is 213800XFW6MKVCHHPW88.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCPKNBNFBDDOKD